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There are many success stories about Medicine
Tourism, relevant to India. Greg Jefferys, an
Australian student was diagnosed with hepatitis C
infection which was fast advancing to cirrhosis of
the liver. He urgently needed about 84 tablets of the
wonder drug, Sovaldi, made by the Gilead Company
which would cost around $ 100,000. He could not
afford it and was desperate. Luckily, he learned that
the same medicine is available in India legally for
about $ 300. Greg travelled to India and reached
Apollo Hospital in Chennai. He was examined by
a qualified gastroenterologist who wrote him the
required prescription. From a licensed pharmacy,
on producing the prescription, Greg obtained the
medicine sufficient for the whole course of the
treatment. Within 11 days, all his liver functions had
returned to normal and within four weeks, there was
no virus detectable in the blood. He was cured. Even
after allowing for his flight and hotel expenses, he
had saved about $ 80,000.
Ms Sun Wei, from Shenyang, a city in northeast China,
underwent treatment in her home town for hepatitis
with interferon. Even after one year, there was no
improvement. The weekly interferon injections were
giving her headache and causing hair loss. She had
heard about the new drug, Sovaldi. But in China,
hospitals were not using Sovaldi because of its high
cost. Sun Wei came to Delhi. She purchased Sovaldi
tablets, enough for a full course, from a registered
pharmacy based on her doctor`s prescription. It was
all perfectly legal and transparent.
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A gastroenterologist from Narayana Health city,
Bangalore, treats at least two new hepatitis patients
from abroad every day. Another consultant at
Columbia Asia Hospital said that about 40% of the
patients he treats are from outside India. The total
treatment cost comes to about Rs 70,000, while it
costs about a crore abroad.
Lu Young, a leukaemia patient, was arrested by the
police in Yuanjiang, a city in China for smuggling
Indian made medicines. Lu had bought a month`s
supply of the Indian generic version of Glivec for
about 2000 Yuan ($ 32), which in China actually cost
about 23,000 Yuan. Glivec was not covered by health
insurance in most places. Lu also distributed the
medicine to about thousand other patients. When Lu
was arrested, a number of people, whom Lu helped
and their families petitioned the government not to
punish Lu.
These are some of the examples of a new
phenomenon called, “Medicine Tourism”. It is NOT
“Medical Tourism”. In Medical tourism, patients
come to India for minor and major surgery or
other treatments. In Medicine tourism, persons in
need come to India only for the sake of purchasing
medicine which is affordable. Throughout the world,
there are several companies who organize package
tours, which includes round-trip flight, a four-star
hotel stay, consultation with doctors and medicine.
Some of them also offer a few days sightseeing
trips or holiday in Rajasthan or Goa along with the
treatment.
Today, several life-saving patented drugs are priced
beyond the reach of the common man, even in
developed countries. For such thousands of patients,
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the only hope is the inexpensive generic versions of
the drugs available in India.
When India adopted the product patent regimen,
there was a fear that the Indian pharmaceutical
industry will not be able to provide cheaper and
affordable medicine anymore. This fear was present
not only in India but also in other developing and
under-developed countries which greatly depend on
the generic drugs from India to provide affordable
medicine to its citizens.
Indian pharmaceutical industry responded to
this challenge in several ways. Indian companies
filed several pre and post grant oppositions under
Section 3(d) of the Indian Patent Act. This resulted
in the denial of patents to several important drugs.
The celebrated example is the case of Glivec, an
anticancer drug, whose patent was rejected. This
made it possible for the cancer patients in India to get
their monthly dosage of Glivec for about Rs 10,000
compared to Rs 1.2 lakh charged by Novartis. This
is also the reason for Lu Young and other desperate
cancer patients of the world go to the extent of
smuggling the medicine from India.
By resorting to the provision of “Compulsory
License”, India throttled the attempts of Bayer to
sell yet another life-saving cancer drug, Nexavar, at
an exorbitant price. Bayer was selling this patented
drug at a price of about Rs 280,000 ($ 5,500) for
a monthly dose of 120 tablets. After obtaining
compulsory license, Natco Pharma marketed the
same medicine at Rs 8,880. It is no surprise that
Nexavar is another generic medicine from India
which attracts “Medicine Tourism”.
More fascinating case is that of “Sovaldi,” the
crucial and most effective medicine for hepatitis C

infection. It was outrageously priced by the patent
holder, Gilead Sciences, at $ 1000 per tablet and $
84,000 for a full 12 week course of the treatment in
USA. In spite of medical insurance, a large number
of patients were left out because of the price. WHO
studies compellingly showed that the treatment
remains unaffordable in large number of countries.
Gilead was wise enough to read the writing on the
wall. In an attempt to forestall the criticism and to
avoid the reputational damage, Gilead approached
several Indian generic companies with a licensing
agreement for making and selling Sovaldi at a highly
discounted price in developing countries. True to its
reputation, the Indian generic companies brought
down the price and Sovaldi was available in Indian
market at a retail price of around $ 300 for 28 tablet
course compared to $ 84,000 in USA. Unfortunately,
license agreement conditions with Gilead did not
allow the low-cost benefit to reach people in affluent
countries. Because of this reason, Greg, Sun Wei
and other patients of the world had to make a
beeline to India to get the medicine triggering the
phenomenon of “Medicine Tourism”.
Thus, although Gilead had a patent on Sovaldi,
it had to go for licensing with Indian generic
companies. This example was replicated with other
anti-hepatitis drugs by other companies. Many
other class of drugs such as anti-HIV have also been
added to the list of most wanted drugs. In all these
cases, the innovator company holding the patent,
ultimately had to approach India for making their
medicine affordable.
All this again shows that India is still considered
as the “Pharmacy of the World” and the Indian
Pharmaceutical Industry is the Health keeper of the
World.
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